Novavax is the fifth drugmaker to enter phase 3 trials for a COVID-19 vaccine in the U.S. Its vaccine uses more traditional technology than Pfizer and Moderna’s and doesn’t require ultra-cold storage, which makes it easier to distribute, according to The Hill.
The drugmaker is enrolling up to 30,000 people for the trial at 115 sites across the U.S. and Mexico. It’s already begun late-stage trials in the U.K. and had to delay the U.S. trial because of manufacturing issues.
“Trial sites were selected in locations where transmission rates are currently high to accelerate the accumulation of positive cases that could show efficacy,” Novavax said in a news release.
More articles on pharmacy:
Pfizer, Moderna testing COVID-19 vaccines against UK variant
Retailers in mad rush to hire, bring back pharmacists
FDA investigating allergic reactions to Pfizer-BioNTech COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.